MCI-to-normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative |
| |
| Institution: | 1. Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA;2. Veteran Affairs San Diego Healthcare System, San Diego, CA, USA;3. San Diego State University/University of California, San Diego (SDSU/UCSD) Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA;4. Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA;5. Department of Biostatistics, University of California, San Diego, La Jolla, CA, USA;6. Department of Family and Preventative Medicine, University of California, San Diego, La Jolla, CA, USA;1. Alzheimer''s Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d''Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;2. Barcelona βeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;3. Department of Psychology, Brooklyn College and The Graduate Center of CUNY, Brooklyn, NY, USA;4. Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA;5. Center for Alzheimer Research and Treatment, Brigham and Women''s Hosptial and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;6. Florey Institute of Neuroscience and Mental Health, Melbourne, Australia;7. Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia;8. Institute of Memory and Alzheimer''s Disease and Brain and Spine Institute (ICM) Pitié Salpetriere University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris, France;9. Department of Psychiatry, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia;10. Institute for Stroke and Dementia Research, Klinikum der Universität München Ludwig-Maximilians-Universität LMU, Munich, Germany;11. AXA Research Fund & UPMC Chair, Paris, France;12. Department of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany;13. Center of Geriatrics and Gerontology, University Medical Center Freiburg, Freiburg, Germany;14. Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA;15. Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA;p. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA;q. Department of Neurology, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands;r. Department of Epidemiology and Biostatistics, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands;s. Neuroscience Campus Amsterdam, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands;t. Department of Psychology, University of Victoria, Victoria, BC, Canada;u. Institute on Aging and Lifelong Health, University of Victoria, Victoria, BC, Canada;v. Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA;w. Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany;x. German Center for Neurodegenerative Disorders (DZNE), Bonn-Cologne, Germany;y. Department of Psychiatry, University Hospital Cologne, Medical Faculty, Cologne, Germany;1. Department of Psychiatry, University of Bonn, Bonn, Germany;2. Clinical Treatment and Research Center for Neurodegenerative Disease (KBFZ), University of Bonn, Bonn, Germany;3. German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany;4. Department of Neurology, Harvard Medical School, Brigham and Women''s Hospital, Massachusetts General Hospital, Boston, MA, USA;5. Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Maastricht University, Maastricht, The Netherlands;6. Institut des Neurosciences des Systèmes, Université de Marseille, Marseille, France;7. INSERM, U1077, Caen, France;8. Université de Caen Basse-Normandie, UMR-S1077, Caen, France;9. Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France;10. CHU de Caen, U1077, Caen, France;11. Université Pierre et Marie Curie, Paris, France;12. INSERM U708, Neuroepidemiology, CIC-EC7 and Bordeaux University, Bordeaux, France;13. Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Melbourne, Australia;14. Alzheimer Center, Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands;15. Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA;p. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA;q. Alzheimer''s Disease and Other Cognitive Disorders Unit, IDIBAPS, Hospital Clinic, Barcelona, Spain;r. Department of Neurology, Mayo Clinic, Rochester, MN, USA;s. Brooklyn College of The City University of New York, New York, NY, USA;t. The Graduate Center of The City University of New York, New York, NY, USA;u. Silberstein Aging and Dementia Research Center, New York University School of Medicine, New York, NY, USA;v. Centre for Healthy Brain Ageing, University of New South Wales, Sydney, Australia;w. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA;x. Dementia Collaborative Research Centre, School of Psychiatry, UNSW Medicine, University of New South Wales, Sydney, Australia;y. Institute of Psychiatry, King''s College London, London, UK;z. Alzheimer''s Institute, Groupe Hospitalier Pitié-Salpêtrière, Paris, France;11. Department of Internal Medicine and Geriatrics, Toulouse University Hospital, UMR INSERM 1027, University Paul Sabatier, Toulouse, France;1. Department of Psychiatry & Neuropsychology, Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands;2. Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA;3. Knight Alzheimer''s Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA;4. Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA;5. Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands;1. Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden;2. Department of Neurology, Skåne University Hospital, Lund, Sweden;3. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden;4. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden;5. Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, United Kingdom;6. UK Dementia Research Institute at UCL, London, United Kingdom;7. Euroimmun AG, Lübeck, Germany;8. Memory Clinic, Skåne University Hospital, Malmö, Sweden |
| |
| Abstract: | IntroductionThe low mild cognitive impairment (MCI) to cognitively normal (CN) reversion rate in the Alzheimer's Disease Neuroimaging Initiative (2-3%) suggests the need to examine reversion by other means. We applied comprehensive neuropsychological criteria (NP criteria) to determine the resulting MCI to CN reversion rate.MethodsParticipants with CN (n = 641) or MCI (n = 569) were classified at baseline and year 1 using NP criteria. Demographic, neuropsychological, and Alzheimer's disease biomarker variables as well as progression to dementia were examined across stable CN, reversion, and stable MCI groups.ResultsNP criteria produced a one-year reversion rate of 15.8%. Reverters had demographics, Alzheimer's disease biomarkers, and risk-of-progression most similar to the stable CN group and showed the most improvement on neuropsychological measures from baseline to year 1.DiscussionNP criteria produced a reversion rate that is consistent with, albeit modestly improved from, reversion rates in meta-analyses. Reverters’ biomarker profiles and progression rates suggest that NP criteria accurately tracked with underlying pathophysiologic status. |
| |
| Keywords: | Mild cognitive impairment Reversion Diagnostic criteria Stability Neuropsychology Alzheimer's disease |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
